Cochrane · systematic review · CD009285
Tiotropium versus placebo for chronic obstructive pulmonary disease
Karner, C, Chong, J, Poole, P · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 4 · 57.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTiotropium versus placebo for chronic obstructive pulmonary disease
Population: people with COPD who have smoked for ≥ 10 pack‐years
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life (SGRQ) Scale 0 to 100, where 100 represents worst possible health status and 0 indicates best possible health status Tiotropium vs placebo | no estimate extracted | 9 studies · 13034 participants | High |
Number of patients with a clinically significant improvement (≥ 4 units) in quality of life (SGRQ) Tiotropium vs placebo | OR 1.52 [1.38, 1.68] | 9 studies · 11672 participants | High |
Number of patients with a clinically significant worsening (≥ 4 units) in quality of life (SGRQ) Tiotropium vs placebo | OR 0.65 [0.59, 0.72] | 9 studies · 11672 participants | High |
Number of patients with one or more exacerbations Tiotropium vs placebo | OR 0.78 [0.7, 0.87] | 22 studies · 23309 participants | High |
Number of patients with one or more exacerbations requiring hospitalisation Tiotropium vs placebo | OR 0.85 [0.72, 1] | 21 studies · 22852 participants | Moderate |
Number of patients with one or more hospitalisations for any cause Tiotropium vs placebo | OR 1 [0.88, 1.13] | 19 studies · 20963 participants | Moderate |
Mortality Tiotropium vs placebo | OR 0.98 [0.86, 1.11] | 22 studies · 23309 participants | Moderate |
Tiotropium versus placebo for chronic obstructive pulmonary disease
Population: people with COPD who have smoked for ≥ 10 pack‐years
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Quality of life (SGRQ) Scale 0 to 100, where 100 represents worst possible health status and 0 indicates best possible health status Tiotropium vs placebo | no estimate extracted | 9 studies · 13034 participants | High |
Number of patients with a clinically significant improvement (≥ 4 units) in quality of life (SGRQ) Tiotropium vs placebo | OR 1.52 [1.38, 1.68] | 9 studies · 11672 participants | High |
Number of patients with a clinically significant worsening (≥ 4 units) in quality of life (SGRQ) Tiotropium vs placebo | OR 0.65 [0.59, 0.72] | 9 studies · 11672 participants | High |
Number of patients with one or more exacerbations Tiotropium vs placebo | OR 0.78 [0.7, 0.87] | 22 studies · 23309 participants | High |
Number of patients with one or more exacerbations requiring hospitalisation Tiotropium vs placebo | OR 0.85 [0.72, 1] | 21 studies · 22852 participants | Moderate |
Number of patients with one or more hospitalisations for any cause Tiotropium vs placebo | OR 1 [0.88, 1.13] | 19 studies · 20963 participants | Moderate |
Mortality Tiotropium vs placebo | OR 0.98 [0.86, 1.11] | 22 studies · 23309 participants | Moderate |
Mortality when using dry powder inhaler Tiotropium vs placebo | OR 0.92 [0.8, 1.05] | 19 studies · 16787 participants | Moderate |
Mortality when using soft mist inhaler Tiotropium vs placebo | OR 1.47 [1.04, 2.08] | 3 studies · 6522 participants | Moderate |